Keywords: alexion, eculizumab, trial, ra, fully, enrolled, pharmaceuticals

Alexion eculizumab trial in RA fully enrolled

Article | 10 February 2003

Alexion Pharmaceuticals has completed enrollment in its Phase IIb trialof eculizumab, its monoclonal antibody targetting complement C5, in patients with ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Drugs

eculizumab

Soliris

Go to drug listing